Shattuck Labs’ (STTK) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Shattuck Labs (NASDAQ:STTK) in a research note issued to investors on Thursday morning,Benzinga reports.

A number of other analysts have also weighed in on STTK. HC Wainwright reiterated a “neutral” rating on shares of Shattuck Labs in a research note on Thursday. Leerink Partnrs raised shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Finally, Leerink Partners initiated coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Trading Down 7.5 %

Shares of NASDAQ:STTK opened at $1.06 on Thursday. Shattuck Labs has a 12 month low of $0.94 and a 12 month high of $11.76. The company has a market capitalization of $50.37 million, a price-to-earnings ratio of -0.69 and a beta of 1.66. The firm’s 50-day moving average is $1.24 and its 200 day moving average is $1.48.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, March 27th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. As a group, equities analysts forecast that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Prosight Management LP boosted its stake in Shattuck Labs by 15.1% in the fourth quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock valued at $8,033,000 after acquiring an additional 873,409 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Shattuck Labs by 37.0% during the 4th quarter. Millennium Management LLC now owns 201,214 shares of the company’s stock valued at $243,000 after purchasing an additional 54,322 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Shattuck Labs by 476.4% in the 4th quarter. Deutsche Bank AG now owns 116,868 shares of the company’s stock worth $141,000 after purchasing an additional 96,594 shares in the last quarter. Bank of America Corp DE grew its stake in Shattuck Labs by 135.0% during the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock worth $226,000 after buying an additional 107,491 shares during the last quarter. Finally, 683 Capital Management LLC purchased a new position in Shattuck Labs during the 4th quarter worth $1,270,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.